NCT07567859尚未招募1 期
An Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Preliminary Efficacy of HS-10587 in Patients With Methylthioadenosine Phosphorylase (MTAP)-Deleted Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.0 个研究点目标入组 362 人开始时间: 2026年6月4日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 362
研究概览
简要总结
This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HS-10587 in patients with MTAP-deleted advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who voluntarily participate in this clinical study, understand the study procedures, and are able to sign a written ICF.
- •Participants with locally advanced or recurrent metastatic malignant solid tumors confirmed by histopathology or cytopathology who have failed or are intolerant to at least one line of prior standard treatment, or for whom no standard treatment exists.
- •Evidence of MTAP deletion in the tumor tissue.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥12 weeks.
- •At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- •Female participants of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed; male participants are willing to use barrier contraception.
排除标准
- •History of other primary malignancies.
- •Presence of pleural/abdominal effusion or pericardial effusion requiring clinical intervention.
- •Presence of leptomeningeal metastasis, spinal cord compression, or brainstem metastasis; known untreated brain metastases, or symptomatic/unstable brain metastases.
- •Participants who have any Grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 6.0) from prior anti-tumor therapies (except alopecia, pigmentation, and residual neurotoxicity).
- •Inadequate bone marrow reserve or hepatic and renal functions.
- •Severe, uncontrolled, or active cardiovascular diseases.
- •Severe or poorly controlled diabetes.
- •Severe or poorly controlled hypertension.
- •Severe infection within 4 weeks prior to the first dose.
- •Long-term corticosteroid therapy, history of other acquired/congenital immunodeficiency disorders, or organ transplantation.
- •Known active infectious diseases.
- •Clinically significant gastrointestinal dysfunction.
- •Moderate to severe pulmonary diseases that seriously affect respiratory function.
- •Prior history of severe neurological or mental disorders.
- •Female participants who are pregnant or breastfeeding, or plan to become pregnant during the study.
- •History of severe allergies, or history of hypersensitivity reactions to any active or inactive ingredients of HS-10587 or to drugs with similar chemical structures to HS-10587 or drugs of the same class as HS-
- •Participants with any conditions that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.
研究组 & 干预措施
HS-10587 Monotherapy
Experimental
Dose escalation cohorts and dose expansion cohorts of varying doses of HS-10587
干预措施: HS-10587 (Drug)
研究者
相似试验
招募中
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid TumorsNCT07310134Nanjing Zenshine Pharmaceuticals80
招募中
1 期
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid TumorsNCT07380334Jiangsu HengRui Medicine Co., Ltd.200
尚未招募
1 期
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor SubjectsNCT07446153Jiangsu HengRui Medicine Co., Ltd.282
招募中
1 期
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid TumorsNCT07348042Xian-Jun Yu198
招募中
1 期
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)NCT07426419Affinia Therapeutics22